Buonpane Christie L, Lautz Timothy B, Langer Monica
Ann and Robert H. Lurie Children's Hospital of Chicago.
Feinberg School of Medicine, Northwestern University, Chicago, IL.
J Pediatr Hematol Oncol. 2022 Mar 1;44(2):43-46. doi: 10.1097/MPH.0000000000002098.
Most children with cancer utilize a central venous line (CVL) for treatment. Complications often necessitate early replacement, revision, or addition (RRA), but the rate of these procedures is not known. This study sought to determine rates of RRA in pediatric oncology patients, and associated risk factors.
Data queried from the Pediatric Health Information System including patients ≤18 years old with malignancy and CVL placement. Analysis included: first CVL placement of the calendar year and subsequent procedures for 6 months thereafter.
A total of 6553 children met inclusion criteria (55.9% male, median age 6 years, interquartile range: 2 to 12). RRA within 6 months was required in 25.6% of patients, with 1.7% requiring 5 or more lines. Patients with Central Line-Associated Bloodstream Infection (CLABSI) were 2.78 times more likely to require RRA within 6 months of initial CVL placement, but accounted for only 16% of RRA patients. Factors associated with RRA were age below 1 year, CLABSI, hematologic malignancy, malnutrition, clotting disorder, deep vessel thromboembolism, and obesity. Patients with implantable ports as initial CVL (42%) were less likely to need RRA.
Twenty-five percent require at least 1 RRA within 6 months, with associated morbidity and costs. Though strongly associated, most revisions were not related to CLABSI episodes.
大多数癌症患儿在治疗过程中会使用中心静脉导管(CVL)。并发症常常需要早期更换、修复或增加(RRA),但这些操作的发生率尚不清楚。本研究旨在确定儿科肿瘤患者的RRA发生率及相关危险因素。
从儿科健康信息系统查询数据,包括年龄≤18岁的恶性肿瘤患者及CVL置入情况。分析内容包括:日历年的首次CVL置入及此后6个月内的后续操作。
共有6553名儿童符合纳入标准(55.9%为男性,中位年龄6岁,四分位间距:2至12岁)。25.6%的患者在6个月内需要RRA,其中1.7%的患者需要5根或更多导管。中心静脉导管相关血流感染(CLABSI)患者在首次CVL置入后6个月内需要RRA的可能性是其他患者的2.78倍,但仅占RRA患者的16%。与RRA相关的因素包括1岁以下、CLABSI、血液系统恶性肿瘤、营养不良、凝血障碍、深部血管血栓栓塞和肥胖。初始CVL为植入式端口的患者(42%)需要RRA的可能性较小。
25%的患者在6个月内至少需要1次RRA,这会带来相关的发病率和成本。虽然密切相关,但大多数修复操作与CLABSI发作无关。